|
| View:
Latest News | Top Stories |
|
| 1.
|
Health Discovery Corporation Appoints Tom Gallagher, Former Wall Street Attorney & a Vice President at Goldman, Sachs & Co., to Head the Company's Global Intellectual Property Strategies
-
Business Wire
-
1 hour, 22 minutes ago
SAVANNAH, Ga.----Health Discovery Corporation is pleased to announce that the Company has appointed Thomas Gallagher as Executive Vice President and Managing Director of Global IP Strategies, charged with executing new revenue-producing licensing and development relationships in the non-healthcare and high tech industries thereby significantly expanding upon HDC’s focus in the healthcare and personalized medicine arena.
|
|
| 2.
|
Amgen Highlights Data to be Presented at ASH
-
PR Newswire
-
1 hour, 31 minutes ago
Amgen Inc. today announced that it will present updated long-term safety and efficacy data for Nplate® in adult chronic immune thrombocytopenic purpura . Additionally, Amgen will present the first Nplate study in a pediatric setting as well as in patients with myelodysplastic syndromes at the 2009 American Society of Hematology Annual Meeting and Exposition .
|
|
| 3.
|
NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults
-
PR Newswire
-
2 hours, 17 minutes ago
Novavax, Inc. announced today it has completed enrollment in the Phase II clinical study of its trivalent seasonal influenza VLP vaccine candidate in healthy adults 60 years of age or older .
|
|
| 4.
|
Three Lou Gehrig's Disease (ALS) Organizations Grant Funding for Research Collaboration Between RXi Pharmaceuticals and UMass Medical School
-
Business Wire
-
Mon 7:00 am ET
WORCESTER, Mass.----Three prominent philanthropic organizations – The Angel Fund, The ALS Therapy Alliance and Project ALS -- dedicated to finding a treatment for amyotrophic lateral sclerosis have financed a new collaboration between one of the world’s leading ALS researchers and RXi Pharmaceuticals Corporation , a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference .
|
|
| 5.
|
Micromet to Present Updates on Clinical Trials with Blinatumomab at Annual Meeting of American Society of Hematology
-
PR Newswire
-
Mon 7:00 am ET
Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will present new results from its clinical studies with blinatumomab at the 51st annual meeting of the American Society of Hematology from December 5-8, 2009 in New Orleans, Louisiana.
|
|
| 6.
|
Theravance Announces That EMEA Has Completed the Validation Phase for the Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections
-
Marketwire
-
Mon 7:00 am ET
|
|
| 7.
|
Eurand Launches ZENPEP(TM) (Pancrelipase) Delayed-Release Capsules
-
Marketwire
-
Mon 7:00 am ET
|
|
| 8.
|
New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents
-
PR Newswire
-
Mon 1:30 am ET
Cell Therapeutics, Inc. announced today that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell lines.
|
|
| 9.
|
Skymark Research Initiates Independent Research Coverage on Sequenom, Inc.
-
GlobeNewswire
-
Wed Nov 25
CALGARY, Alberta -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Sequenom, Inc. . Skymark Research is currently offering a complimentary trial subscription.
|
|
| 10.
|
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
-
PR Newswire
-
Wed Nov 25
Dendreon Corporation today announced that management will present at the following two investor conferences next month.
|
|
